NEW YORK (GenomeWeb News) – Seeking a share of a market estimated at around $1 billion, GenomeDx plans to launch its first test aimed at prostate cancer during the first half of this year, CEO Doug Dolginow said.

Based on whole-genome analysis to profile RNA expression signatures, the test measures the aggressiveness of prostate cancer in patients who have had a prostatectomy. Typically, after the surgery, a doctor will monitor a patient's prostate-specific antigen levels to evaluate whether the cancer has returned and whether follow-up treatment is needed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.